Monoclonal antibody to a human prothymocyte antigen and methods of preparing same

Claim 2

A monoclonal antibody of class IgG produced by a hybridoma formed by fusion of cells from mouse myeloma line and spleen cells from a mouse previously immunized with human leukemic T-ALL cells, which antibody: (a) reacts with approximately 95 percent of normal human thymocytes, 5 percent of normal human peripheral T cells, 10 percent of E - peripheral mononuclear cells (B cells and null cells), and 10-20 percent of bone marrow cells; (b) reacts with 92 percent of untreated thymocytes, 75 percent of thymocytes previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8002 and complement, 86 percent of thymocytes previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8001 and complement, and 85 percent of the thymocytes previously treated with monoclonal antibody produced by hybrid cell line ATCC CRL 8014 and complement; (c) is reactive with an antigen on leukemic T-ALL cells; and (d) reacts with HSB-2, CEM and MOLT-4 cell lines.

Claim 3

The monoclonal antibody of claim 1 which is of subclass IgG 1 .

Claim 4

The monoclonal antibody of claim 1 which is produced from a hybridoma formed by fusion of P3X63Ag8U1 myeloma cells and spleen cells from a CAF 1 mouse previously immunized with human leukemic T-ALL cells.

Claim 5

A monoclonal antibody of class IgG produced by a hybridoma formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with human leukemic T-ALL cells which reacts with approximately 95 percent of normal human thymocytes, 5 percent of normal human peripheral T cells, 10 percent of E - peripheral mononuclear cells (B cells and null cells), and 10-20 percent of bone marrow cells.

Claim 6

A monoclonal antibody of class IgG produced by a hybridoma formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with human leukemic T-ALL cells which reacts with approximately 95 percent of normal human thymocytes, 5 percent of normal human peripheral T cells, 10 percent of E - peripheral mononuclear cells (B cells and null cells), and 10-20 percent of bone marrow cells.

Claim 7

Mouse monoclonal antibody which reacts with approximately 95% of normal human thymocytes, 5% of normal human peripheral T cells, 10% of E peripheral mononuclear cells (B cells and null cells) and 10-20% of bone marrow cells.

Claim 8

Mouse monoclonal antibody which reacts with approximately 95% of normal human thymocytes, 5% of normal human peripheral T cells, 10% of E peripheral mononuclear cells (B cells and null cells) and 10-20% of bone marrow cells.

Claim 9

A monoclonal antibody which reacts with approximately 95% of normal human thymocytes, 5% of normal human peripheral T cells, 10% of E - peripheral mononuclear cells (B cells and null cells) and 10-20% of bone marrow cells, prepared by the method which comprises the steps of: (i) immunizing mice with human leukemic T-ALL cells; (ii) removing the spleens from said mice and making a suspension of the spleen cells; (iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; (v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells or human thymocytes; (vi) selecting and cloning a hybridoma producing antibody which reacts with approximately 95% of normal human thymocytes, 5% of normal human peripheral T cells, 10% of E - peripheral mononuclear cells (B cells and null cells and 10-20% of bone marrow cells; and (vii) recovering the antibody from the supernatant above said clones.

Claim 10

A monoclonal antibody which reacts with approximately 95% of normal human thymocytes, 5% of normal human peripheral T cells, 10% of E - peripheral mononuclear cells (B cells and null cells) and 10-20% of bone marrow cells, prepared by the method which comprises the steps of: (i) immunizing mice with human leukemic T-ALL cells; (ii) removing the spleens from said mice and making a suspension of the spleen cells; (iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; (v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells or human thymocytes; (vi) selecting and cloning a hybridoma producing antibody which reacts with approximately 95% of normal human thymocytes, 5% of normal human peripheral T cells, 10% of E - peripheral mononuclear cells (B cells and null cells and 10-20% of bone marrow cells; and (vii) recovering the antibody from the supernatant above said clones.

Claim 11

A monoclonal antibody which reacts with approximately 95% of normal human thymocytes, 5% of normal human peripheral T cells, 10% of E peripheral mononuclear cells (B cells and null cells) and 10-20% of bone marrow cells, prepared by the method which comprises the steps of: (i) immunizing mice with human leukemic T-ALL cells; (ii) removing the spleens from said mice and making a suspension of the spleen cells; (iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; (v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells or human thymocytes; (vi) selecting and cloning a hybridoma producing antibody which reacts with approximately 95% of normal human thymocytes, 5% of normal human peripheral T cells, 10% of E - peripheral mononuclear cells (B cells and null cells) and 10-20% of bone marrow cells; and (vii) transferring said clones intraperitoneally into mice; and (viii) harvesting the malignant ascites or serum from said mice, which ascites or serum contains the desired antibody.

Claim 12

A monoclonal antibody which reacts with approximately 95% of normal human thymocytes, 5% of normal human peripheral T cells, 10% of E peripheral mononuclear cells (B cells and null cells) and 10-20% of bone marrow cells, prepared by the method which comprises the steps of: (i) immunizing mice with human leukemic T-ALL cells; (ii) removing the spleens from said mice and making a suspension of the spleen cells; (iii) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (iv) diluting and culturing the fused cells in separate wells in a medium which will not support the unfused myeloma cells; (v) evaluating the supernatant in each well containing a hybridoma for the presence of antibody to E rosette positive purified T cells or human thymocytes; (vi) selecting and cloning a hybridoma producing antibody which reacts with approximately 95% of normal human thymocytes, 5% of normal human peripheral T cells, 10% of E - peripheral mononuclear cells (B cells and null cells) and 10-20% of bone marrow cells; and (vii) transferring said clones intraperitoneally into mice; and (viii) harvesting the malignant ascites or serum from said mice, which ascites or serum contains the desired antibody.

Claim 15

The monoclonal antibody prepared by the method of claim 8.

Claim 18

The monoclonal antibody prepared by the method of claim 10.